Conclusion
We conclude that Infliximab exerts favorable impact in terms of lowering the mortality rate of SARS-CoV-2 infection. More studies on the effects of Infliximab on severe COVID-19 should be conducted [28].
1. Tenforde, M.W. and R. Link-Gelles, Reduction in COVID-19-related mortality over time but disparities across population subgroups. Lancet Public Health, 2023. 8 (5): p. e327-e328.
2. Del Borgo, C., et al., Effectiveness, Tolerability and Prescribing Choice of Antiviral Molecules Molnupiravir, Remdesivir and Nirmatrelvir/r: A Real-World Comparison in the First Ten Months of Use.Viruses, 2023. 15 (4).
3. Jiang, Y., et al., Inflammatory pathways in COVID-19: Mechanism and therapeutic interventions. MedComm (2020), 2022. 3 (3): p. e154.
4. Horby, P., et al., Dexamethasone in Hospitalized Patients with Covid-19. N Engl J Med, 2021. 384 (8): p. 693-704.
5. Cowan, J., A. Amson, A. Christofides, and Z. Chagla, Monoclonal antibodies as COVID-19 prophylaxis therapy in immunocompromised patient populations. Int J Infect Dis, 2023. 134 : p. 228-238.
6. Velez, M.P. and M.W. McCarthy, Infliximab as a potential treatment for COVID-19. Expert Rev Anti Infect Ther, 2023.21 (1): p. 1-5.
7. Guo, Y., et al., Targeting TNF-α for COVID-19: Recent Advanced and Controversies. Front Public Health, 2022. 10 : p. 833967.
8. Shafiee, G., et al., Post COVID-19 neuropsychiatric complications and therapeutic role for TNF-α inhibitors: a case series study. J Diabetes Metab Disord, 2022. 21 (2): p. 2013-2016.
9. Mohd Zawawi, Z., et al., Prospective Roles of Tumor Necrosis Factor-Alpha (TNF-α) in COVID-19: Prognosis, Therapeutic and Management. Int J Mol Sci, 2023. 24 (7).
10. Fatima, R., K. Bittar, and M. Aziz, Infliximab , inStatPearls . 2023, StatPearls Publishing
Copyright © 2023, StatPearls Publishing LLC.: Treasure Island (FL).
11. Jang, D.I., et al., The Role of Tumor Necrosis Factor Alpha (TNF-α) in Autoimmune Disease and Current TNF-α Inhibitors in Therapeutics. Int J Mol Sci, 2021. 22 (5).
12. Farrokhpour, M., et al., Infliximab and Intravenous Gammaglobulin in Hospitalized Severe COVID-19 Patients in Intensive Care Unit. Arch Iran Med, 2021. 24 (2): p. 139-143.
13. O’Halloran, J.A., et al., Abatacept, Cenicriviroc, or Infliximab for Treatment of Adults Hospitalized With COVID-19 Pneumonia: A Randomized Clinical Trial. Jama, 2023. 330 (4): p. 328-339.
14. Melong Pianta Taleng, C.M., et al., Incidence of COVID-19 in patients treated with infliximab compared with patients treated with rituximab. RMD Open, 2021. 7 (3).
15. Stallmach, A., et al., Infliximab against severe COVID-19-induced cytokine storm syndrome with organ failure-a cautionary case series. Crit Care, 2020. 24 (1): p. 444.
16. Kokkotis, G., et al., Systematic review with meta-analysis: COVID-19 outcomes in patients receiving anti-TNF treatments. Aliment Pharmacol Ther, 2022. 55 (2): p. 154-167.
17. Avni, T., et al., Tocilizumab in the treatment of COVID-19-a meta-analysis. Qjm, 2021. 114 (8): p. 577-586.
18. Halim, C., A.F. Mirza, and M.I. Sari, The Association between TNF-α, IL-6, and Vitamin D Levels and COVID-19 Severity and Mortality: A Systematic Review and Meta-Analysis. Pathogens, 2022. 11 (2).
19. Cherian, J.J., et al., Efficacy and safety of baricitinib and tocilizumab in hospitalized patients with COVID-19: A comparison using systematic review and meta-analysis. Front Pharmacol, 2022.13 : p. 1004308.
20. Amstutz, A., et al., Effects of remdesivir in patients hospitalised with COVID-19: a systematic review and individual patient data meta-analysis of randomised controlled trials. Lancet Respir Med, 2023. 11 (5): p. 453-464.
21. Gohda, T., et al., Circulating tumor necrosis factor receptors are associated with mortality and disease severity in COVID-19 patients. PLoS One, 2022. 17 (10): p. e0275745.
22. Sarhan, N.M., et al., Evaluation of infliximab/tocilizumab versus tocilizumab among COVID-19 patients with cytokine storm syndrome. Sci Rep, 2023. 13 (1): p. 6456.
23. Ray, K., Antibody responses to SARS-CoV-2 infection are attenuated in infliximab-treated patients with IBD. Nat Rev Gastroenterol Hepatol, 2021. 18 (5): p. 286.
24. Hernandez, A.V., et al., Beneficial and Harmful Effects of Monoclonal Antibodies for the Treatment and Prophylaxis of COVID-19: Systematic Review and Meta-Analysis. Am J Med, 2022. 135 (11): p. 1349-1361.e18.
25. Lai, C.C., et al., The Clinical Efficacy and Safety of Anti-Viral Agents for Non-Hospitalized Patients with COVID-19: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials. Viruses, 2022. 14 (8).
26. Schoehl, J., et al., Severe Acute Respiratory Distress Syndrome during Infliximab Therapy in a Patient with Crohn Disease.Case Rep Gastroenterol, 2016. 10 (3): p. 574-580.
27. Yoo, J.Y., et al., Comparative analysis of COVID-19 guidelines from six countries: a qualitative study on the US, China, South Korea, the UK, Brazil, and Haiti. BMC Public Health, 2020. 20 (1): p. 1853.
28. Coldewey, S.M., et al., Infliximab in the treatment of patients with severe COVID-19 (INFLIXCOVID): protocol for a randomised, controlled, multicentre, open-label phase II clinical study. Trials, 2022. 23 (1): p. 737.